Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Wilms Tumor Associated With the 9q22.3 Microdeletion Syndrome

2 New Case Reports and a Review of The Literature

Cayrol, Julie MBBS*,†; Nightingale, Michael MBBS; Challis, Jacqueline B App Sc§; Campbell, Martin MBBS*; Sullivan, Michael MBBS, PhD*,†; Heloury, Yves MD

Journal of Pediatric Hematology/Oncology: October 26, 2018 - Volume Publish Ahead of Print - Issue - p
doi: 10.1097/MPH.0000000000001322
Clinical and Laboratory Observations: PDF Only
Buy
SDC
PAP

Background: The 9q22.3 syndrome is an autosomal dominant microdeletion syndrome with similarities to Gorlin syndrome (GS). It encompasses the PTCH1 gene locus that harbors mutations for GS. Although the 9q22.3 syndrome is associated with Wilms tumor (WT), WT is not a GS-associated tumor, implying a different mechanism involving PTCH1, or a different locus in the 9q22.3 region. The goal of this study is to report the association between WT and 9q22.3 syndrome and review the outcome of treatment.

Observations: We report 2 new cases of WT with 9q22.3 deletion and review the literature. Among the 44 described patients with 9q22.3 deletion, 7 developed WT (16%) at a mean age of 45 months (range, 4 to 84 mo). All patients had dysmorphic features, macrocephaly, and developmental delay, and there was an association with overgrowth (4/7). One patient had bilateral WT, another had a synchronous rhabdomyosarcoma. The outcome was excellent with all cases reported to be in complete remission.

Conclusions: The 9q22.3 microdeletion syndrome should be considered at diagnosis of WT in children with dysmorphic features. Conversely, patients with a known 9q22.3 deletion syndrome should be considered for a WT predisposition surveillance program, especially those with overgrowth. The management should be individualized and given the excellent prognosis, and the unknown future risk of metachronous disease or other malignancy, the surgical approach should be carefully considered.

*Children’s Cancer Centre

Departments of Paediatric Surgery

Paediatric Urology, The Royal Children’s Hospital

Department of Paediatrics, The University of Melbourne, Parkville

§Victorian Clinical Genetics Services, Murdoch Children’s Research Institute, Melbourne, Vic., Australia

M.S. and Y.H. contributed equally.

The authors declare no conflict of interest.

Reprints: Julie Cayrol, MBBS, Children’s Cancer Centre. The Royal Children’s Hospital, 50 Flemington Road, Parkville, Melbourne, Vic. 3052, Australia (e-mail: Julie.Cayrol@rch.org.au).

Received April 4, 2018

Accepted August 21, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.